Skip to content

A Message To Our Clients

A Message To Our Clients

To Our Clients,


First of all, I hope everyone is staying safe and healthy in these unprecedented times.  I want to assure you that Arfinn Med has systems in place to ensure that our workflows are not impacted from having staff work remotely and we will continue to provide the same quality product and customer service that you have become accustomed to.  If you have any questions regarding our Business Continuation Plan, please reach out to info@arfinnmed.com.


We understand that routines will be temporarily changed in the coming months, so we are adapting to accommodate this change.  This means building out a more robust telemedicine system, increasing our patient portal functionality,  generating consents to be e-signed, and streamlining our patient intake process to cut down on wait times.  


As we settle into new workflows and challenges, we will suspend all monthly fees for using Arfinn Med until June 1st.  We also will activate our full suite of functionality to all current users so you are able to offer the best care to patients in the interim.  We know this doesn’t seem like much in these times, but we want to show our gratitude to the medical professionals who are on the front lines helping patients get the help they desperately need.  If you haven’t already, you will be seeing these updates on your account over the weekend. 


Please stay safe, and let us know if you require anything to continue running your practices.  I have set aside a development team to continually assess how to improve care and keep stakeholders safe.
Sincerely, 


James West CEO

Stories you may be interested in

Alternative Mississippi medical marijuana program barely wins approval from Senate

JACKSON • Legislation that would create a new medical marijuana program in Mississippi if the voter-approved Initiative 65 is overturned in court cleared the state Senate on the second try last week early on Friday morning. Senate Bill 2765, the Mississippi Medical Cannabis Act, failed by a single vote Thursday evening. But six hours later, after…
Read More

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More

European Parliament Passes Cannabis Resolution, Joins WHO In Supporting Medical Marijuana

Following reports about the World Health Organization (WHO) recommending a rescheduling of cannabis and several of its key components under international drug treaties, the European Parliament voted on Wednesday on a resolution that would help advance medical cannabis in the countries that form the European Union. Read the full story here.
Read More

CEO Spotlight: James West

As a former academic coordinator for the City University of New York Research Foundation and Medgar Evers College, CEO and co-founder of Arfinn Med, James West, has extensive experience in adult education and professional training programming. James put this extensive education to good use when he noticed that there was a direct need for a…
Read More

Finally, Georgia can grow medical marijuana. Here’s what you need to know.

Four years ago, Governor Nathan Deal signed into law Haleigh’s Hope Act, which made low-THC cannabis oil legal to use by those with certain medical conditions. However, as it was still against the law to buy or grow marijuana in the state, it was virtually impossible to obtain the oil in Georgia. Patients were forced…
Read More

Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders

Report of the Guideline Development Subcommittee of the American Academy of Neurology:   We performed a systematic review of medical marijuana (1948–November 2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy, and movement disorders. We graded the studies according to the American Academy of Neurology classification scheme for therapeutic articles. Read the full…
Read More

Leave a Comment

You must be logged in to post a comment.